|
Mar30
|
Blue agave is a fruit used to make tequila. Natural compounds from this fruit have been found in earlier laboratory studies to be potentially effective in the delivery of drugs to the colon than conventional drug-carriers. Such were the findings of chemists at the University of Guadalajara in Mexico which could lead to improved treatments for ulcerative colitis, irritable bowel syndrome, cancer, Crohn's disease and other colon diseases. According to the study’s researchers:
The tequila compounds, a class of polysaccharides known as fructans, were developed by the scientists in Mexico into tiny microspheres that are capable of carrying existing drugs that are used to treat colon diseases. Because the compounds resist destruction in the stomach, they could allow more of the drugs to reach the colon intact and improve their effectiveness.
The study’s findings have recently been presented at the 233rd national meeting of the American Chemical Society. Find more details from the full report. [photo credit: andrew.stottsan.net]
|
|
Mar30
|
Clinical trials for NicOx S.A. (EPA: COX)’s new experimental medicine for the treatment of glaucoma - PF-03187207 - has recently been initiated by Pfizer Inc. (NYSE: PFE) following USFDA’s approval of its Investigational New Drug (IND) approval for PF-03187207, which...
Continue Reading
|
|
|
Sponsored Review How do you find information on dental implants when you have no idea where to begin your research? Most of us would simply call the 800 number we know so well, but OsseoNews: Dental Implant News and Discussion...
Continue Reading
|
|
Mar29
|
A wholly-owned subsidiary of DelSite Biotechnologies, Inc. – Carrington Laboratories Inc. (Nasdaq: CARN) has entered into a collaborative agreement with the International Vaccine Institute (IVI) to evaluate DelSite's drug delivery technology for sublingual vaccines that can be used for needle-free...
Continue Reading
|
|
|
Dong-A PharmTech Co., Ltd. (SEO:000640) has recently completed its 340 patient phase 2b "at-home" clinical study for udenafil – the company’s new long acting (12 hour half-life) oral phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction (ED). Udenafil was approved...
Continue Reading
|
|
|
A specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders- Adams Respiratory Therapeutics, Inc. (Nasdaq: ARXT) - has entered into a license and collaboration agreement with MonoSol...
Continue Reading
|
|
|
StormBio, Inc. and Imperial Innovations Group plc have entered into an agreement to license patents and know-how for development of a novel therapy for life-threatening influenza and other inflammatory diseases. The said agreement allows StormBio to develop a novel therapeutic...
Continue Reading
|
|
|
The USFDA has granted two separate fast track designations to Nuvelo, Inc. (Nasdaq: NUVO)’s product candidate rNAPc2: for first-line treatment of metastatic colorectal cancer (mCRC) to improve progression-free survival and overall survival when added to Avastin®-containing 5-flurourocil (5-FU)-based chemotherapy regimensfor...
Continue Reading
|
|
|
Co-developed by Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP), REMICADE® (infliximab) was first approved in the U.S. ( by the USFDA) in 1998 as treatment U.S. for adult Crohn's disease (CD) and later, in 2005, for adult ulcerative colitis. REMICADE®...
Continue Reading
|
|
Mar27
|
The U.S. Department of Agriculture has conditionally approved a novel therapeutic vaccine for the treatment of canine melanoma – a common but deadly form of cancer in dogs. Canine melanoma is an aggressive form of cancer that typically appears in...
Continue Reading
|
|
|
Tekturna® (aliskiren) and Diovan® (valsartan) are both cardiovascular drugs from Novartis (VTX: NOVN).Tekturna® is the first USFDA-approved direct renin inhibitor which works by directly targeting an enzyme that triggers a process that can lead to high blood pressure, it has...
Continue Reading
|
|
|
Schering-Plough Corporation (NYSE: SGP) has entered into an agreement with Merck & Co., Inc. (NYSE: MRK) to initiate the development of a new cholesterol-lowering drug by combining ezetimibe and atorvastatin. Past collaborations between these two companies created ZETIA® (ezetimibe) and VYTORIN®...
Continue Reading
|
|
|
The European Medicines Agency (EMEA) has granted a positive opinion on Celgene Corporation (Nasdaq: CELG)’s novel oral cancer drug REVLIMID® (lenalidomide) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least...
Continue Reading
|
|
Mar26
|
Vion Pharmaceuticals, Inc. (Nasdaq: VION) has recently extended its manufacturing agreement with SAFC (a member of the Sigma-Aldrich Group) for its lead anticancer agent Cloretazine® (VNP40101M). The extended agreement will allow SAFC to continue the manufacture of Cloretazine® (VNP40101M) active...
Continue Reading
|
|
|
In lieu of World TB Day, Eli Lilly and Co. (NYSE: LLY) has announced its plans to invest an additional $50 million in an innovative, global partnership to fight Multi-Drug Resistant Tuberculosis (MDR-TB). According to Sidney Taurel, Lilly's chairman and...
Continue Reading
|
|
|
ONCONASE® (ranpirnase), a first-in-class therapeutic based on Alfacell Corporation's proprietary ribonuclease (RNase) technology is a natural protein isolated from the leopard frog, which has been shown (in both laboratory and clinical setting) to target cancer cells while sparing normal cells:...
Continue Reading
|
|
|
A study from the King’s College, London has demonstrated the ability of Martek Bioscience’s life’sDHA™ in reduction of diastolic blood pressure in middle-aged subjects. A vegetarian form of DHA omega-3, life'sDHA™ is made from microalgae under tightly controlled manufacturing conditions,...
Continue Reading
|
|
Mar25
|
China Biopharma, Inc. (OTC: CBPC)’s Chinese subsidiary - Hainan CITIC Biopharmaceutical Development Co., Ltd. - has entered into a distribution agreement with Takeda Pharmaceutical Company, Ltd. (TYO: 4502).As part of Takeda's goal to expand sales channels in Asia, China Biopharma...
Continue Reading
|
|
|
Chromos Molecular Systems Inc. (TSE: CHR) has recently entered into an agreement with Pain Therapeutics, Inc. (NASDAQ: PTIE) for the development of a cell line utilizing Chromos' ACE System. Chromos' ACE System is a versatile and potent biological engineering system...
Continue Reading
|
|
|
Cleveland BioLabs, Inc. (Nasdaq: CBLI) has recently received a development fund (between $1.3 and $2.4 million) from Defense Threat Reduction Agency (DTRA) of the Department of Defense (DoD) for the development leading to the acquisition of its radiation countermeasure compound,...
Continue Reading
|
|
|
MINRAD International, Inc.’s exclusive distribution partner in Japan – Merck Seiyaku – has received marketing approval from Japanese Ministry of Health for Sevoflurane. An interventional pain management company, MINRAD International, Inc. (AMEX: BUF) has real time image guidance and anesthesia...
Continue Reading
|
|
|
Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC) has recently filed a Special Protocol Assessment (SPA) to the US FDA for the design of a phase III trial of combination therapy for women with advanced lung cancer. The said trial, known as PGT307, will...
Continue Reading
|
|
Mar24
|
Preclinical studies of Amicus Therapeutics (706165)’ Plicera™ (isofagomine tartrate, AT2101) revealed that it can increase levels of the target enzyme in cells derived from a patient with the N370S mutation and in mice that express the L444P mutation – the two...
Continue Reading
|
|
|
Data obtained by ImmuneRegen BioSciences on its Substance P analog – Homspera™ - suggests that the compound has potential value as a co-therapeutic agent or vaccine adjuvant for influenza and acute radiation syndrome therapeutics. The Company believes that, in conjunction...
Continue Reading
|
|
|
NOXAFIL® (posaconazole) Oral Suspension, an antifungal agent by Schering-Plough Corporation (NYSE: SGP) has received a category 1 recommendation (1) (highest rating) for preventing certain invasive fungal infections (IFIs) in high-risk cancer patients and a category 2B recommendation (2) for preventing...
Continue Reading
|
|
|
A new treatment for severe malaria - Intravenous (IV) Artesunate – will be developed and commercialized under a collaborative research and development agreement between the Walter Reed Army Institute of Research (WRAIR), the U.S. Army Medical Materiel Development Activity (USAMMDA),...
Continue Reading
|
|
Mar23
|
Pardon my recent absence in this blog. I wish I could say i was on vacation...well, sort of...because I took a forced blog hiatus for two days and exchanged the internet/blogosphere for two seasons of Grey's Anatomy which I just...
Continue Reading
|
|
|
Leading developer of innovative software solutions that optimize the business performance of life sciences organizations around the world, DecisionView, Inc. has signed a multi-year agreement with GlaxoSmithKline (NYSE: GSK) for the standardization of DecisionView's StudyManager application for optimizing clinical recruitment...
Continue Reading
|
|
Mar20
|
Evotec AG (FRA: EVT) has recently entered into a multi-year collaboration with Boehringer Ingelheim to jointly identify novel targets as potential points of intervention in the treatment of Alzheimer's disease (AD). The Research Institute of Molecular Pathology in Vienna (IMP)...
Continue Reading
|
|
|
Akesis Pharmaceuticals, Inc. (OTC: AKES) has entered into an exclusive license and commercialization agreement with the University of British Columbia for bis(ethylmaltolato) oxovanadium (IV) or BEOV – a novel vanadium compound that has shown potential for the treatment of type...
Continue Reading
|
|
|
The top-line positive results of Phase 2 efficacy trial of Dimebon™ in patients with mild-to-moderate Alzheimer's disease have recently been presented by Medivation, Inc. (Amex: MDV) in an oral presentation (abstract #1662) at the 8th International Conference on Alzheimer's and...
Continue Reading
|
|
Mar18
|
Founded in 2005 by Paramount BioSciences, LLC, TRACON Pharmaceuticals is a privately held biopharmaceutical company focused on the development of products for cancer treatment, including agents that inhibit angiogenesis. Micromet, Inc. on the other hand, is a biopharmaceutical company focused...
Continue Reading
|
|
|
Exelixis, Inc. (Nasdaq: EXEL) has recently submitted an investigational new drug (IND) application to the USFDA for its candidate anticancer compound XL147. XL147 is a novel, orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). In...
Continue Reading
|
|
|
The USFDA has recently approved Soliris™ (eculizumab) for the treatment of all patients with paroxysmal nocturnal hemoglobinuria (PNH). A product of Alexion Pharmaceuticals, Inc., (Nasdaq: ALXN), Soliris™ is the first therapy ever approved for PNH and is indicated for the...
Continue Reading
|
|
Mar17
|
Abeille Pharmaceuticals, Inc. and SymBio Pharmaceuticals have entered into an exclusive license and distribution agreement for the development and marketing of AB-1001 in Japan, China (including Hong Kong), Korea, Taiwan and Singapore. AB-1001 is Abeille's transdermal patch for emesis or...
Continue Reading
|
|
|
A subsidiary of China’s Aida Pharmaceuticals, Inc. (OTC: AIDA) - Shanghai Qiaer Biotechnology – has initiated the preclinical research of the company’s potential anti-cancer treatment Vasostatin-Apo2L. A recombinant fusion protein, Vasostatin-Apo2L is a potential tumor growth inhibitor. The treatment may...
Continue Reading
|
|
|
GlaxoSmithKline’s breast cancer drug TYKERB® has recently been approved by the USFDA for advanced or metastatic breast cancer. In lieu of this approval, GSK confirmed that TYKERB® (lapatinib) will be available through Commitment to Access – the company’s program which...
Continue Reading
|
|
Mar16
|
A Special Protocol Assessment (SPA) has been submitted by Cell Therapeutics, Inc. (Nasdaq: CTIC) to the U.S. Food and Drug Administration (FDA) for the design of its phase III trial of pixantrone for patients with indolent non- Hodgkin's lymphoma (NHL)....
Continue Reading
|
|
|
Currently without a USFDA-approved acute therapy in the United States, Hereditary Angioedema (HAE) or hereditary C1-inhibitor deficiency is a rare and life-threatening inflammatory condition characterized by recurrent attacks of inflammation affecting the extremities (the hands and feet), the face, the...
Continue Reading
|
|
|
The USFDA has granted an Orphan Drug Designation to cethromycin for the prophylactic treatment of patients exposed to inhalation anthrax. Cethromycin - a second generation ketolide antibiotic undergoing Phase III clinical trial for the treatment of respiratory tract infections –...
Continue Reading
|
|
|
The USFDA has recently accepted the New Drug Application (NDA) submitted by Adams Respiratory Therapeutics, Inc. (Nasdaq: ARXT) for 600 mg and 1200 mg oral solid extended release guaifenesin combination products for the prescription treatment of cough. The said NDA...
Continue Reading
|
|
|
Tyrima™ - a member of a novel class of drugs known as reversible inhibitors of monoamine oxidase A or RIMAs – is CeNeRx BioPharma, Inc.’s lead candidate for the treatment of depression and anxiety passed its first human trial (Phase...
Continue Reading
|
|
Mar15
|
A product of Sucampo Pharmaceuticals, Inc. (706843) - AMITIZA® (lubiprostone) – has been approved in January 2006 by the USFDA for the treatment of Chronic Idiopathic Constipation (CIC) in adults. Now, Sucampo has commenced two clinical studies of AMITIZA® (lubiprostone)...
Continue Reading
|
|
|
Array BioPharma Inc. (Nasdaq: ARRY) and VentiRx Pharmaceuticals Inc. have entered into a license agreement granting VentiRx exclusive worldwide rights to Array's Toll-like receptor (TLR) program. According to Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx: "These...
Continue Reading
|
|
|
Virax Holdings Limited (ASX: VHL) has entered into a license agreement with the French biopharmaceutical company, Transgene S.A. (EPA: TNG) which grants Transgene an exclusive access to Virax's Co-X-Gene™ technology patents for use in two of Transgene's immunotherapeutic products, TG4010...
Continue Reading
|
|
Mar14
|
Let’s see if today’s blogosphere might interest us pharma blog readers… At Allergizer: First OTC Nasal Sprays for Headache, Allergy and Sinus Relief : Sinol® Nasal Sprays, Launched by STG Media Corp. At Cancer Commentary: Novel Vaccine against Chemo-resistant Ovarian...
Continue Reading
|
|
|
Chemokine Therapeutics Corp. (TSE:CTI) is a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular disease. CTE- 9908 is the company’s anti-cancer drug candidate - a peptide analog of the Chemokine SDF-1, and an antagonist of its...
Continue Reading
|
|
|
Its Board of Directors has approved Schering-Plough Corporation (NYSE: SGP)’s transaction to acquire Organon BioSciences N.V. - the human and animal health care businesses of Akzo Nobel N.V. (AMS: AKZOY). The said transaction, expected to close by the end of...
Continue Reading
|
|
|
Oxxon Therapeutics Limited (7725872) is a private UK-based company developing innovative, antigen-specific immunotherapies to treat patients with cancer and chronic infectious diseases. Based in Oxford, UK, Oxford BioMedica (SEA: OXB) is a publicly traded biopharmaceutical company focused on the development...
Continue Reading
|
|
Mar12
|
Interim clinical data of La Jolla Pharmaceutical Company (Nasdaq: LJPC)’s ongoing double-blind, placebo-controlled randomized Lupus Phase 3 trial of Riquent® (abetimus sodium) revealed positive antibody results. Analyses of interim antibody data indicate that patients treated with 900 mg or 300...
Continue Reading
|
|
|
Tamiflu® is indicated for the prevention and treatment of influenza types A and B in patients one year and older and is currently available in a 75 mg capsule for adults and as liquid suspension formulation for children. Roche –maker...
Continue Reading
|
|
Mar 9
|
Once more, here are some pharma-related science/health/medical blog posts that you might find interesting and useful: At Cancer Commentary: Green Tea Polyphenol + COX-2 Inhibitor Can Slow Progression of Prostate Cancer At Diabetes Notes: Depression Treatment May Help Long Term...
Continue Reading
|
|
|
Non-prescription Inflame Away™-Celadrin® is available in two forms: a softgel and a topical cream application. A new clinical study - the fourth clinical study performed on the efficacy of Celadrin® during the past six years – demonstrated that Celadrin® can...
Continue Reading
|
|
|
In a statement recently issued by the National Medical Association (NMA), it is encouraging “the appropriate use of the Human Papillomavirus (HPV) vaccine, but believes that patient participation should be voluntary." According to Albert W. Morris, M.D., President of the...
Continue Reading
|
|
|
Lipitor® Tablets has been approved by the USFDA for the following new indications: to reduce the risk of nonfatal heart attacks, fatal and non-fatal strokes, certain types of heart surgery, hospitalization for heart failure, and chest pain; in patients with...
Continue Reading
|
|
|
Moli1901, a novel investigative compound for the treatment of cystic fibrosis (CF) is being developed by AOP Orphan Pharmaceuticals AG in Europe under a licensing and commercialization agreement with Lantibio, Inc. The two companies have recently announced the positive final...
Continue Reading
|
|
Mar 7
|
Fentanyl TAIFUN® is a fast-acting fentanyl formulation delivered using LAB International Inc. (TSE: LAB)’s TAIFUN® dry powder inhaler platform. The company has recently announced the positive results from its open-label Phase IIb clinical trial of Fentanyl TAIFUN® which demonstrated successful...
Continue Reading
|
|
|
Hovione LLC (10316445) agreed to license its dry powder inhaler technology, jointly to Sankyo Company Ltd. (TYO: 6417)) and Biota Holdings Ltd. (ASX: BTA) for the delivery of long acting neuraminidase inhibitors (LANI). The long acting neuraminidase inhibitors (LANI) -...
Continue Reading
|
|
|
A privately held neuroscience drug discovery company focused on sleep disorders – Hypnion, Inc. – has recently signed a definitive merger agreement with Eli Lilly and Company (NYSE: LLY), allowing Lilly to acquire Hypnion. Hypnion stockholders have already approved the...
Continue Reading
|
|
|
Actimmune® (interferon gamma-1b), under Phase III clinical trial has been found not significantly beneficial in patients with idiopathic pulmonary fibrosis (IPF) compared to placebo – enough for the study’s independent data monitoring committee (DMC) to recommend discontinuation of the trial.The Phase...
Continue Reading
|
|
Mar 6
|
Clinical data of a completed Phase 2 follow-up study of Flurizan™ in patients with mild Alzheimer's disease indicate that Flurizan may be capable, not only of slowing the decline of Alzheimer's disease, but of halting the disease in its tracks....
Continue Reading
|
|
|
Enterotoxigenic E. coli (ETEC) bacteria is the most common cause of traveler’s diarrhea (affecting 20-50 % of international travelers to areas where the bacteria is endemic), to which there is no vaccine available in the United States. Currently, to avoid...
Continue Reading
|
|
|
Phase IIa trials conducted by Transition Therapeutics Inc. (TSE: TTH) for its regenerative product, E1-I.N.T.™, demonstrated safety, efficacy and tolerability in type 1 and type 2 diabetes patients. Data from the trial in type 2 diabetes patients demonstrated that E1-I.N.T.™...
Continue Reading
|
|
|
Though found safe and generally well tolerated, Memory Pharmaceuticals Corp. (Nasdaq: MEMY)’s MEM 1003 did not prove effective for the treatment of acute mania in bipolar disorder, as revealed by clinical data from a Phase 2a study supported by the...
Continue Reading
|
|
Mar 5
|
A drug delivery company - Dermatrends, Inc. – has entered into an agreement with Teikoku Pharma USA (8887877) to develop a prototype patch formulation for the transdermal delivery of a widely used anti-psychotic pharmaceutical compound. The terms of agreement include...
Continue Reading
|
|
|
A majority-owned subsidiary of Arrowhead Research Corporation (Nasdaq: ARWR) - Insert Therapeutics – has signed a definitive agreement with R&D Biopharmaceuticals in which it will acquire an exclusive, world-wide license to multiple second generation epothilone anticancer drugs. Epothilones are naturally...
Continue Reading
|
|
|
The EMEA Committee for Medicinal Products for Human Use (CHMP) has already expressed two positive opinions to Wyeth Pharmaceuticals’ application to extend the indication of PREVENAR™ (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed) to include active immunization against pneumonia and acute otitis...
Continue Reading
|
|
|
The European Medicines Agency (EMEA) has accepted for review Pharmion Corporation (Nasdaq: PHRM)’s Marketing Authorization Application (MAA) (submitted in January 2007) for Thalidomide Pharmion (thalidomide) for the treatment of untreated multiple myeloma – the second most common cancer of the...
Continue Reading
|
|
Mar 4
|
Vaprisol® (conivaptan hydrochloride injection), an arginine vasopressin (AVP) receptor antagonist, has been approved by the USFDA for the intravenous treatment of hypervolemic hyponatremia in hospitalized patients. Discovered and developed by Astellas Pharma, Inc. (TYO: 4503), Vaprisol® is the first drug...
Continue Reading
|
|
|
The Chinese State Food and Drug Administration (SFDA) has recently approved SEBIVO® (Telbivudine) as a once-a-day treatment, taken orally with or without food, for the treatment of chronic hepatitis B (CHB). Telbivudine received regulatory approval in the United States from...
Continue Reading
|
|
Mar 3
|
What: 2007 BIO International Convention When: May 6-9 2007 Where: Boston Convention & Exhibition Center Boston, Massachusetts, USA 2007 BIO International Convention is the global event for biotechnology. Click here to register. Former award-winning actor, now Parkinson's disease patient advocate...
Continue Reading
|
|
Mar 2
|
Marketed by Janssen, L. P. (12381409), RISPERDAL® (risperidone) is approved in the United States for the treatment of acute manic or mixed episodes of Bipolar I Disorder and for the treatment of schizophrenia in adults. Also, RISPERDAL® was approved in...
Continue Reading
|
|
|
MAP Pharmaceuticals’ inhaled migraine drug candidate - Tempo™ - passed two phase 2 clinical trials. The first Phase 2 study demonstrated clinically significant results in a randomized, outpatient, placebo-controlled study at nine U.S. headache centers. In addition, a second Phase...
Continue Reading
|
|
Mar 1
|
Currently, there are over 300 medicines under development to treat or prevent hundreds of rare diseases, as recently reported by the Pharmaceutical Research and Manufacturers of America (PhRMA). The National Institutes of Health estimates that there are approximately 6,000 rare...
Continue Reading
|
|
|
Evotec AG (FRA: EVT) and Interprotein Corporation (previously IntercytoNanoScience Co., Ltd.) have signed a collaboration agreement on Interprotein's Interleukin 6 (IL-6) inhibitors programme for the development of novel, orally active drugs against inflammatory diseases. IL-6 is a crucial cytokine involved...
Continue Reading
|
|
|
The USFDA has approved Cerenia™ (maropitant citrate) – a product of Pfizer Animal Health (PAH) - the first medication to prevent and treat acute vomiting in dogs. Vomiting is one of the most common reasons owners take their dogs to...
Continue Reading
|